Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

RECRUITING

Identifier: CI-TRIAL-00102996
Entity page: /trial/NCT07036133 ↗
Edges: 3

Neighbours: 2 cancers1 drugs
Drawn: 3 of 3 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment condition of …CONDITION_OFderived2 of 2
← condition of	Hematopoietic and Lymphoid Cell Neoplasm registry condition “Hematologic Malignancies” mapped PROBABILISTIC	—	—	Hematopoietic and Lymphoid Cell Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Solid Neoplasm

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment intervention of …INTERVENTION_OFderived1 of 1
← intervention of	Pralatrexatesmall molecule registry intervention “Pralatrexate Injection” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment intervention of …INTERVENTION_OFderived1 of 1

← intervention of

Pralatrexatesmall molecule

registry intervention “Pralatrexate Injection” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

Radial view

Every edge, grouped by relationship

Paths